Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies

The use of blood derivatives represents an alternative therapeutic approach that is gaining interest in regenerative medicine due to its potential to stimulate and accelerate tissue healing. Autologous serum eye drops and platelet‐enriched plasma eye drops are being used in the treatment of different ophthalmological disorders. In this review, we summarize the different blood‐derived formulations used in the treatment and care of ocular surface disorders. The biological basis and use of autologous serum and plasma rich in growth factors are deeply evaluated as well as the challenges to be addressed in the future in this new generation of blood‐derived therapies.

[1]  W. Stark,et al.  Autologous serum eye drops for dry eye. , 2017, The Cochrane database of systematic reviews.

[2]  H. Ullum,et al.  Ready‐made allogeneic ABO‐specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy , 2014, Acta ophthalmologica.

[3]  M. Méndez,et al.  Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study , 2014, Acta ophthalmologica.

[4]  M. Ávila.  Restoration of Human Lacrimal Function Following Platelet-Rich Plasma Injection , 2014, Cornea.

[5]  G. Orive,et al.  Biological Stability of Plasma Rich in Growth Factors Eye Drops After Storage of 3 Months , 2013, Cornea.

[6]  G. Orive,et al.  Plasma rich in growth factors (PRGF-Endoret) stimulates corneal wound healing and reduces haze formation after PRK surgery. , 2013, Experimental eye research.

[7]  A. Roszkowska,et al.  Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome , 2013, Acta ophthalmologica.

[8]  J. Alió,et al.  Autologous fibrin membrane combined with solid platelet-rich plasma in the management of perforated corneal ulcers: a pilot study. , 2013, JAMA ophthalmology.

[9]  J. Alió,et al.  Bovine Pericardium Membrane (Tutopatch) Combined With Solid Platelet-Rich Plasma for the Management of Perforated Corneal Ulcers , 2013, Cornea.

[10]  K. Yoon,et al.  Application of umbilical cord serum eyedrops after laser epithelial keratomileusis , 2013, Acta ophthalmologica.

[11]  A. Delcampe,et al.  Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. , 2012, Investigative ophthalmology & visual science.

[12]  L. Scudeller,et al.  Autologous platelet lysate for treatment of refractory ocular GVHD , 2012, Bone Marrow Transplantation.

[13]  H. Kim,et al.  Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis , 2012, Japanese Journal of Ophthalmology.

[14]  T. Dada,et al.  Topical Autologous Platelet-Rich Plasma Eyedrops for Acute Corneal Chemical Injury , 2012, Cornea.

[15]  J. Durán,et al.  In vitro effects of three blood derivatives on human corneal epithelial cells. , 2012, Investigative ophthalmology & visual science.

[16]  G. Orive,et al.  Perspectives and challenges in regenerative medicine using plasma rich in growth factors. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[17]  J. Durán,et al.  Efficacy of Plasma Rich in Growth Factors for the Treatment of Dry Eye , 2011, Cornea.

[18]  G. Orive,et al.  Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1-Induced myodifferentiation. , 2011, Investigative ophthalmology & visual science.

[19]  G. Orive,et al.  The use of plasma rich in growth factors (PRGF-Endoret) in the treatment of a severe mal perforant ulcer in the foot of a person with diabetes. , 2011, Diabetes research and clinical practice.

[20]  Won Choi,et al.  Application of Umbilical Cord Serum Eyedrops for Recurrent Corneal Erosions , 2011, Cornea.

[21]  R. Tandon,et al.  Evaluation of umbilical cord serum therapy in acute ocular chemical burns. , 2011, Investigative ophthalmology & visual science.

[22]  Murat Dogru,et al.  Pharmacotherapy of dry eye , 2011, Expert opinion on pharmacotherapy.

[23]  J. Durán,et al.  Plasma Rich in Growth Factors as a Therapeutic Agent for Persistent Corneal Epithelial Defects , 2010, Cornea.

[24]  Gorka Orive,et al.  Potential of endogenous regenerative technology for in situ regenerative medicine. , 2010, Advanced drug delivery reviews.

[25]  Y. Çağlar,et al.  The Effect of Subconjunctival Platelet-Rich Plasma on Corneal Epithelial Wound Healing , 2010, Cornea.

[26]  C. Fonte,et al.  Blood components for topical use in tissue regeneration: evaluation of corneal lesions treated with platelet lysate and considerations on repair mechanisms. , 2010, Blood transfusion = Trasfusione del sangue.

[27]  F Luengo Gimeno,et al.  In vivo lamellar keratoplasty using platelet-rich plasma as a bioadhesive , 2010, Eye.

[28]  E. Toker,et al.  Corneal and Conjunctival Sensitivity in Patients With Dry Eye: The Effect of Topical Cyclosporine Therapy , 2010, Cornea.

[29]  G. Geerling,et al.  Albumin-Augentropfen zur Behandlung von Augenoberflächenerkrankungen , 2009, Der Ophthalmologe.

[30]  J. Torres-Macho,et al.  Effect of platelet-rich plasma on sinus lifting: a randomized-controlled clinical trial. , 2009, Journal of clinical periodontology.

[31]  R. Flaumenhaft,et al.  Platelet alpha-granules: basic biology and clinical correlates. , 2009, Blood reviews.

[32]  A. Behrens,et al.  Autologous serum for ocular surface diseases. , 2008, Arquivos brasileiros de oftalmologia.

[33]  M. Lemp,et al.  Advances in understanding and managing dry eye disease. , 2008, American journal of ophthalmology.

[34]  P. Nurden,et al.  Platelets and wound healing. , 2008, Frontiers in bioscience : a journal and virtual library.

[35]  K. Tsubota,et al.  Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease , 2008, Bone Marrow Transplantation.

[36]  G. Orive,et al.  Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. , 2008, Journal of biomedical materials research. Part B, Applied biomaterials.

[37]  G. Orive,et al.  The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. , 2007, Biomaterials.

[38]  J. Durán,et al.  Laser in situ keratomileusis flap necrosis after trigeminal nerve palsy. , 2007, Archives of ophthalmology.

[39]  J. Alió,et al.  Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. , 2007, Ophthalmology.

[40]  H. Sheardown,et al.  Growth factors in the tear film: role in tissue maintenance, wound healing, and ocular pathology. , 2007, The ocular surface.

[41]  K. Yoon,et al.  Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. , 2007, American journal of ophthalmology.

[42]  J. Alió,et al.  Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. , 2007, Journal of refractive surgery.

[43]  K. Yoon,et al.  Interleukin-6 and Tumor Necrosis Factor-α Levels in Tears of Patients With Dry Eye Syndrome , 2007, Cornea.

[44]  J. Alió,et al.  Symptomatic Dry Eye Treatment with Autologous Platelet-Rich Plasma , 2007, Ophthalmic Research.

[45]  Iñigo Mujika,et al.  Comparison of Surgically Repaired Achilles Tendon Tears Using Platelet-Rich Fibrin Matrices , 2007, The American journal of sports medicine.

[46]  J. Croxatto,et al.  Preparation of platelet-rich plasma as a tissue adhesive for experimental transplantation in rabbits , 2006, Thrombosis journal.

[47]  T. Wedel,et al.  Corneal epitheliotrophic capacity of three different blood-derived preparations. , 2006, Investigative ophthalmology & visual science.

[48]  K. Koyano,et al.  The effect of platelet-rich plasma on the cellular response of rat bone marrow cells in vitro. , 2005, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[49]  G. Geerling,et al.  Autologous serum eye drops for ocular surface disorders , 2004, British Journal of Ophthalmology.

[50]  K. Tsubota,et al.  Autologous serum application in the treatment of neurotrophic keratopathy. , 2004, Ophthalmology.

[51]  T. Nishida,et al.  Role of the C domain of IGFs in synergistic promotion, with a substance P-derived peptide, of rabbit corneal epithelial wound healing. , 2004, Investigative ophthalmology & visual science.

[52]  Paquita Nurden,et al.  Autologous platelets as a source of proteins for healing and tissue regeneration , 2003, Thrombosis and Haemostasis.

[53]  R. Pandey,et al.  Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects , 2003, The British journal of ophthalmology.

[54]  K. Tsubota,et al.  Albumin as a tear supplement in the treatment of severe dry eye , 2003, The British journal of ophthalmology.

[55]  S. Werner,et al.  Regulation of wound healing by growth factors and cytokines. , 2003, Physiological reviews.

[56]  C. Creuzot-Garcher,et al.  Treatment of Persistent Corneal Epithelial Defects by Autologous Serum , 2002 .

[57]  J. Daniels,et al.  Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies , 2001, The British journal of ophthalmology.

[58]  R. Noecker,et al.  Effects of common ophthalmic preservatives on ocular health , 2001, Advances in therapy.

[59]  K. Tsubota,et al.  Successful Treatment of Dry Eye in Two Patients With Chronic Graft-versus-host Disease With Systemic Administration of FK506 and Corticosteroids , 2001, Cornea.

[60]  P. Khaw,et al.  Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. , 2001, Investigative ophthalmology & visual science.

[61]  G. Reed,et al.  Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. , 2000, Blood.

[62]  A. Vigorito,et al.  GVHD dry eyes treated with autologous serum tears , 2000, Bone Marrow Transplantation.

[63]  K. Tsubota,et al.  Treatment of persistent corneal epithelial defect by autologous serum application. , 1999, Ophthalmology.

[64]  S. Pflugfelder,et al.  Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. , 1999, Current eye research.

[65]  E. Anitua.  Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. , 1999, The International journal of oral & maxillofacial implants.

[66]  K. Fukuda,et al.  Treatment of neurotrophic keratopathy with substance-P-derived peptide (FGLM) and insulin-like growth factor I , 1998, The Lancet.

[67]  K. Tsubota,et al.  Treatment of dry eye by autologous serum application in Sjögren’s syndrome , 1998, The British journal of ophthalmology.

[68]  D. Musch,et al.  Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. Chiron Vision Fibronectin Study Group. , 1995, American journal of ophthalmology.

[69]  J. S. Snow,et al.  Ocular effects of topical and systemic steroids. , 1992, Dermatologic clinics.

[70]  J. Pastor,et al.  Epidermal Growth Factor and Corneal Wound Healing: A Multicenter Study , 1992, Cornea.

[71]  Timo Tervo,et al.  EPIDERMAL GROWTH FACTOR (EGF) IN OCULAR FLUIDS: PRESENCE, ORIGIN AND THERAPEUTICAL CONSIDERATIONS , 1992, Acta ophthalmologica. Supplement.

[72]  H. Gadner,et al.  Manifestations of Graft-Versus-Host Disease following Allogenic Bone Marrow Transplantation , 1991, European journal of ophthalmology.

[73]  P. Ness,et al.  Fibrin glue: the perfect operative sealant? , 1990, Transfusion.

[74]  T. M. Phan,et al.  Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers. , 1987, American journal of ophthalmology.

[75]  R. Bone,et al.  Primary Sjogren syndrome: clinical and immunopathologic features. , 1984, Seminars in arthritis and rheumatism.

[76]  J. Belmont,et al.  Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. , 1984, Arthritis and rheumatism.

[77]  W. Dinning.  Steroids and the eye--indications and complications. , 1976, Postgraduate medical journal.

[78]  M. Doane,et al.  Clinical experience with a mobile ocular perfusion pump. , 1975, A M A Archives of Ophthalmology.

[79]  E. Khaksar,et al.  The effect of sub-conjunctival platelet-rich plasma in combination with topical acetylcysteine on corneal alkali burn ulcer in rabbits , 2011, Comparative Clinical Pathology.

[80]  M. Kohlhaas,et al.  [Albumin eye drops for treatment of ocular surface diseases]. , 2009, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[81]  Rafael Márquez de Aracena del Cid,et al.  Subconjunctival application of regenerative factor-rich plasma for the treatment of ocular alkali burns. , 2009, European journal of ophthalmology.

[82]  L. Rivas,et al.  [Use of autologous serum in ophthalmic practice]. , 2007, Archivos de la Sociedad Espanola de Oftalmologia.

[83]  N. Ehlers,et al.  Keratocyte migration and peptide growth factors: the effect of PDGF, bFGF, EGF, IGF-I, aFGF and TGF-beta on human keratocyte migration in a collagen gel. , 1997, Current eye research.

[84]  J. Marks,et al.  [Ulcers]. , 1986, Phlebologie.

[85]  W. Green,et al.  Ocular manifestations of graft-vs-host disease. , 1983, Ophthalmology.